OncoMatch/Clinical Trials/NCT06954584
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Is NCT06954584 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Fluzoparib Monotherapy for ovarian cancer.
Treatment: Bevacizumab · Fluzoparib Monotherapy — Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP inhibitors . In vitro evidence suggests that low-carbohydrate culture conditions may restore PARP inhibitor sensitivity in HRD-negative tumor cells. This study aims to validate the survival benefits of fluzoparib combined with bevacizumab in HRD-positive ovarian cancer patients during first-line maintenance therapy and explore the efficacy of fluzoparib combined with a dietary intervention in HRD-negative populations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Grade: high-grade; grade ≥ii for endometrioid
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Completed platinum-based chemotherapy with the following requirements: * Patients unable to tolerate chemotherapy for definitive reasons must complete at least 4 cycles of platinum-based chemotherapy. * Patients undergoing interval debulking surgery must complete at least 3 cycles of platinum-based chemotherapy post-surgery.
Cannot have received: PARP inhibitor (olaparib, niraparib, rucaparib, pamiparib, fluzoparib)
Prior use of PARP inhibitors (e.g., olaparib, niraparib, rucaparib, pamiparib, fluzoparib)
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L; Platelets ≥90×10⁹/L; Hemoglobin ≥9 g/dL; Serum albumin ≥3 g/dL
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN
Adequate organ function (no blood transfusions or growth factors within 14 days prior to randomization): -Absolute neutrophil count (ANC) ≥1.5×10⁹/L. -Platelets ≥90×10⁹/L. -Hemoglobin ≥9 g/dL. -Serum albumin ≥3 g/dL. -Total bilirubin ≤1.5×ULN. -ALT and AST ≤2.5×ULN. * Serum creatinine ≤1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06954584 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages